PSC
OXFD

Piper Sandler & Co’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History

Piper Sandler & Co’s Portfolio OXFD Stock Details OXFD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-65
Closed -$1K – 20
2016
Q1 		$1K Hold
65
– – ﹤0.01% 17
2015
Q4 		$1K Sell
65
-22,435
-100% -$278K ﹤0.01% 27
2015
Q3 		$304K Sell
22,500
-7,500
-25% -$102K 0.33% 42
2015
Q2 		$416K Buy
30,000
+250
+0.8% +$3.38K 0.25% 44
2015
Q1 		$419K Buy
29,750
+3,750
+14% +$51K 0.17% 55
2014
Q4 		$354K Buy
+26,000
New +$355K 0.17% 45

Other funds holding OXFD

CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Piper Sandler & Co's OXFD Position: Q2 2016 in Review

Piper Sandler & Co sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q2 2016, closing a stake of 65 shares — an estimated $1K sold.

Piper Sandler & Co first reported a position in OXFD in Q4 2014 and held it in 6 quarters. The position peaked at $419K in Q1 2015. 56 funds tracked by Wall St. Rank hold OXFD as of Q2 2016.

  • Piper Sandler & Co reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q2 2016 after selling out during the quarter.
  • Piper Sandler & Co sold 65 Oxford Immunotec Global PLC Ordinary Shares shares in Q2 2016, an estimated $1K.
  • Piper Sandler & Co first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q4 2014 and held it in 6 quarters.
  • Piper Sandler & Co's Oxford Immunotec Global PLC Ordinary Shares position peaked at $419K in Q1 2015.
  • 56 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q2 2016.

Based on Piper Sandler & Co's 13F filing for Q2 2016, filed 15 Aug 2016.